Chesapeake Capital Corp IL Invests $148,000 in Grifols, S.A. (NASDAQ:GRFS)

Chesapeake Capital Corp IL purchased a new position in Grifols, S.A. (NASDAQ:GRFS) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,500 shares of the biotechnology company’s stock, valued at approximately $148,000.

A number of other large investors have also recently made changes to their positions in GRFS. Brandes Investment Partners LP boosted its holdings in shares of Grifols by 8.7% in the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after acquiring an additional 1,481,924 shares during the period. Armistice Capital LLC boosted its holdings in shares of Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after acquiring an additional 1,244,000 shares during the period. Capital World Investors boosted its holdings in shares of Grifols by 4.9% in the first quarter. Capital World Investors now owns 20,749,225 shares of the biotechnology company’s stock worth $138,605,000 after acquiring an additional 961,700 shares during the period. Highland Peak Capital LLC bought a new position in shares of Grifols in the second quarter worth $5,991,000. Finally, Black Creek Investment Management Inc. raised its position in shares of Grifols by 7.7% in the second quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock worth $77,799,000 after buying an additional 881,155 shares in the last quarter.

Grifols Stock Performance

NASDAQ GRFS opened at $9.47 on Monday. The stock’s 50-day simple moving average is $8.87 and its two-hundred day simple moving average is $8.01. Grifols, S.A. has a twelve month low of $5.30 and a twelve month high of $12.15. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.